Condition: Resistant Hypertension

This is a randomized, double-blind, placebo-controlled Phase 2 study to evaluate the efficacy and safety of drug IONIS-AGT-LRx compared to placebo in patients with treatment-resistant hypertension (rHTN).

Location(s): Jacksonville (Headquarters), St. Augustine

Condition: Resistant Hypertension

This is a randomized, double-blind, placebo-controlled, dose-ranging Phase 2 study to evaluate the efficacy and safety of drug CIN-107 compared to placebo in patients with treatment-resistant hypertension (rHTN). The study will assess three oral doses of CIN-107 versus placebo.

Location(s): Jacksonville (Headquarters)

Condition: Resistant Hypertension